ANP32A

Acidic leucine-rich nuclear phosphoprotein 32 family member A · P39687 · ANP32A on Sugi Atlas →

0 patent compounds predicted against ANP32A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to ANP32A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma PHASE1/PHASE2COMPLETED
Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for Progeria PHASE2COMPLETED
Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers PHASE2COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS PHASE2COMPLETED
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis PHASE1/PHASE2COMPLETED
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant PHASE1/PHASE2RECRUITING
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
Phase I Study of Novel Estrogen Receptor(ER) a36 Modifier Icaritin in Advanced Breast Cancer Patients PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Idiopathic Dilated Cardiomyopathy nanCOMPLETED
Diagnostic and Prognostic Role of Troponin and Brain Natriuretic Peptide in Pediatric Patients With Cardiomyopathy in Correlation to Echocardiography Findings nanUNKNOWN
Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors nanNOT_YET_RECRUITING
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Muscle Tissue Bank for Muscular Dystrophy nanCOMPLETED
A-protein Levels in Adult and Pediatric Brain Tumor Patients nanCOMPLETED
Effect of Exercise on the Human Skeletal Muscle Phosphoproteome nanCOMPLETED
Genetic Determinants of Exercise-Induced Muscle Damage (POLYGENDOMUS) nanRECRUITING
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Mapping Novel Disease Genes for Dilated Cardiomyopathy nanCOMPLETED
Biomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) nanRECRUITING
Ischemic Preconditioning - Perspectives of Use Vivio/in Vitro Studies nanENROLLING_BY_INVITATION
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas nanACTIVE_NOT_RECRUITING
Family Blood Pressure Program - SAPPHIRe Network nanCOMPLETED
Nuclear Myosin VI - a Therapeutic Target in Breast Cancer nanUNKNOWN
The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels nanCOMPLETED
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Protein Expression as a Potential Diagnostic Biomarker of Cervical Dysplasia and/or Cancer nanCOMPLETED
Prognostic Value of Protein IMP3 Expression in Cervical Cancer nanCOMPLETED
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ANP32A binder may also engage these)

ProteinNameSimilarity
P51122 1.000 P51122 →
Q7ZUP0 1.000 Q7ZUP0 →
Q8HY67 0.999 Q8HY67 →
Q6PAF6 0.995 Q6PAF6 →
O35381 0.993 O35381 →
Q6A1I3 0.992 Q6A1I3 →
P49911 0.992 P49911 →
Q3SZC6 0.988 Q3SZC6 →
ANP32B Acidic leucine-rich nuclear phosphoprotein 32 family member B 0.988 landscape →
Q6P1U7 0.983 Q6P1U7 →
Q5ZMN0 0.978 Q5ZMN0 →
Q8AVC1 0.977 Q8AVC1 →
Q9EST6 0.974 Q9EST6 →
Q9EST5 0.972 Q9EST5 →
P97822 0.969 P97822 →
Q5F4A3 0.968 Q5F4A3 →
Q6NUW5 0.967 Q6NUW5 →
Q5XIE0 0.964 Q5XIE0 →
Q9BTT0 0.960 Q9BTT0 →
Q7ZY40 0.946 Q7ZY40 →
SET Protein SET 0.924 landscape →
Q28XE2 0.920 Q28XE2 →
Q8N108 0.920 Q8N108 →
Q5REE1 0.919 Q5REE1 →
Q9EQU5 0.917 Q9EQU5 →
Q63945 0.917 Q63945 →
Q5UAK0 0.917 Q5UAK0 →
Q8IZP2 0.915 Q8IZP2 →
Q1RMR5 0.915 Q1RMR5 →
Q5ZKT9 0.914 Q5ZKT9 →